Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
doi: https://doi.org/10.1101/2021.05.03.21256309
Saye H Khoo
1University of Liverpool, UK
2Liverpool University Hospital NHS Foundation Trust, UK
Richard FitzGerald
2Liverpool University Hospital NHS Foundation Trust, UK
Thomas Fletcher
2Liverpool University Hospital NHS Foundation Trust, UK
3Liverpool School of Tropical Medicine, UK
Sean Ewings
4Southampton Clinical Trials Unit, UK
Thomas Jaki
5University of Lancaster, UK
6MRC Biostatistics Unit, University of Cambridge, UK
Rebecca Lyon
2Liverpool University Hospital NHS Foundation Trust, UK
Nichola Downs
4Southampton Clinical Trials Unit, UK
Lauren Walker
2Liverpool University Hospital NHS Foundation Trust, UK
Olana Tansley-Hancock
4Southampton Clinical Trials Unit, UK
William Greenhalf
1University of Liverpool, UK
Christie Woods
2Liverpool University Hospital NHS Foundation Trust, UK
Helen Reynolds
1University of Liverpool, UK
Ellice Marwood
4Southampton Clinical Trials Unit, UK
Pavel Mozgunov
5University of Lancaster, UK
Emily Adams
3Liverpool School of Tropical Medicine, UK
Katie Bullock
1University of Liverpool, UK
Wayne Holman
7Ridgeback Biotherapeutics, Miami, USA
Marcin D Bula
4Southampton Clinical Trials Unit, UK
Jennifer L Gibney
2Liverpool University Hospital NHS Foundation Trust, UK
Geoffrey Saunders
4Southampton Clinical Trials Unit, UK
Andrea Corkhill
4Southampton Clinical Trials Unit, UK
Colin Hale
2Liverpool University Hospital NHS Foundation Trust, UK
Kerensa Thorne
4Southampton Clinical Trials Unit, UK
Justin Chiong
1University of Liverpool, UK
Susannah Condie
4Southampton Clinical Trials Unit, UK
Henry Pertinez
1University of Liverpool, UK
Wendy Painter
7Ridgeback Biotherapeutics, Miami, USA
Emma Wrixon
4Southampton Clinical Trials Unit, UK
Lucy Johnson
4Southampton Clinical Trials Unit, UK
Sara Yeats
4Southampton Clinical Trials Unit, UK
Kim Mallard
4Southampton Clinical Trials Unit, UK
Mike Radford
4Southampton Clinical Trials Unit, UK
Keira Fines
4Southampton Clinical Trials Unit, UK
Victoria Shaw
1University of Liverpool, UK
Andrew Owen
1University of Liverpool, UK
David G Lalloo
3Liverpool School of Tropical Medicine, UK
Michael Jacobs
8Royal Free London NHS Foundation Trust, UK
Gareth Griffiths
4Southampton Clinical Trials Unit, UK
Data Availability
The AGILE Trial Steering Committee will consider all reasonable requests by health-care providers, investigators, and researchers to provide anonymised data to address specific scientific or clinical objectives. The AGILE investigators are committed to reviewing requests from researchers for access to clinical trial protocols, de-identified patient-level clinical trial data, and study-level clinical trial data.
Posted May 05, 2021.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
medRxiv 2021.05.03.21256309; doi: https://doi.org/10.1101/2021.05.03.21256309
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
medRxiv 2021.05.03.21256309; doi: https://doi.org/10.1101/2021.05.03.21256309
Subject Area
Subject Areas
- Addiction Medicine (380)
- Allergy and Immunology (695)
- Anesthesia (186)
- Cardiovascular Medicine (2809)
- Dermatology (241)
- Emergency Medicine (424)
- Epidemiology (12499)
- Forensic Medicine (10)
- Gastroenterology (796)
- Genetic and Genomic Medicine (4364)
- Geriatric Medicine (398)
- Health Economics (711)
- Health Informatics (2813)
- Health Policy (1042)
- Hematology (372)
- HIV/AIDS (888)
- Medical Education (411)
- Medical Ethics (113)
- Nephrology (460)
- Neurology (4132)
- Nursing (219)
- Nutrition (613)
- Oncology (2178)
- Ophthalmology (616)
- Orthopedics (253)
- Otolaryngology (316)
- Pain Medicine (260)
- Palliative Medicine (80)
- Pathology (482)
- Pediatrics (1166)
- Primary Care Research (480)
- Public and Global Health (6720)
- Radiology and Imaging (1475)
- Respiratory Medicine (893)
- Rheumatology (427)
- Sports Medicine (359)
- Surgery (468)
- Toxicology (57)
- Transplantation (197)
- Urology (173)